Jubilant Therapeutics announces preclinical data of dual LSD1 and HDAC6 inhibitor at AACR 2020 - News-Medical.net 24-Jun-2020

Jubilant Therapeutics announces preclinical data of dual LSD1 and HDAC6 inhibitor at AACR 2020 - News-Medical.net

Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that preclinical data of dual LSD1 and HDAC6 inhibitor JBI-802, will be presented i…